Lantheus Holdings, Inc. (LNTH) income statement
LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3017% above fair value
$102.10+0.00 (0.00%)
Close on Nov 20, 2026Market cap $6.66BP/E 24.7Yield –
Lantheus Holdings, Inc. financial ratios
See a number that looks wrong?